- Donate
- Understanding Rare Disease
- Living with a Rare Disease
- Community Support
- Advancing Research
- Driving Policy
- Get Involved
- Rare Disease News
- Resource Library
- About Us
- For Clinicians & Researchers
- For Patient Organizations
Last updated: February 10, 2017
Years published: 2017
NORD gratefully acknowledges the HSAN1E Society and Christopher J. Klein, MD, Professor of Neurology, Mayo Clinic, Rochester, MN, for the preparation of this report.
Hereditary sensory and autonomic neuropathy type 1E (HSAN1E) is a rare genetic disorder. It is considered an adult-onset disorder with symptoms usually starting to occur in the 20-30โs. Although HSAN1E is considered to be a subtype of HSAN, a group of genetic disorders most-ly affecting the sensory and autonomic neurons of the peripheral nervous system, the central nervous system is also severely affected in HSAN1E patients, especially in the later stage of the disease. HSAN1E patients usually have three main symptoms, hearing loss, sensory neu-ropathy, and cognitive decline (dementia), and many have other various symptoms such as sleep disorders and epilepsy. The symptoms are progressive, worsening with age. At this time, there are no available treatments other than management for each specific symptom, (i.e., hearing aids for the hearing loss) and there is currently no cure for HSAN1E. Based on a re-cent study, the average life span of HSAN1E patients is approximately 50 years. HSAN1E is an autosomal dominant genetic disorder caused by a mutation in the DNMT1 gene.
The signs and symptoms of HSAN1E and the age of onset are variable, even within members of the same family. HSAN1E typically runs a 15 to 30 year progressive course.
HSAN1E is an adult-onset disorder with an average onset age of 37 years. All HSAN1E pa-tients have presented with a triad of symptoms: hearing loss, sensory neuropathy, and cogni-tive decline. Bilateral hearing loss is often the first symptom and it continues to get worse over time.
Peripheral neuropathy occurs when nerves that carry messages to and from the brain and spinal cord to the rest of the body are damaged. Those affected may experience tingling, burning, numbness, and stabbing pain. As it progresses, peripheral neuropathy can lead to sores or infections in the feet that donโt heal, weakness, and balance and walking problems.
The cognitive decline (dementia) often starts with personality changes, poor decision making, memory loss, irritability, impulsivity, apathy, and sleepiness.
Some other symptoms of HSAN1E are seizures, auditory or visual hallucinations, renal fail-ure, and sleep disorders.
HSAN1E is caused by a mutation in the DNMT1 gene. Genes provide instructions for creating proteins that play critical roles to allow the body to function normally. When a deleterious mu-tation occurs within a gene, the protein produced will not function normally, and this can af-fect a specific organ or multiple organs of the body. The disease mechanism of the HSAN1E mutations is still being investigated.
The DNMT1 gene is located on the short (p) arm of chromosome 19p13.2. Chromosomes are located on the nucleus of human cells and carry the genetic information for each individual. Human body cells normally have 46 chromosomes. Pairs of human chromosomes numbered from 1 through 22 are called autosomes and the sex chromosomes are designated X and Y. Males have one X and one Y chromosome and females have two X chromosomes. Each chromosome has a short arm designated โpโ and a long arm designated โqโ. Chromosomes are further subdivided into many bands that are numbered. For example, โchromosomes 11p13โ refers to band 13 on the short arm of chromosome 11. The numbered bands specify the location of the thousands of genes that are present on each chromosome.
Most genetic diseases are determined by the status of the two copies of a gene, one received from the father and one from the mother. Dominant genetic disorders occur when only a sin-gle copy of an abnormal gene is necessary to cause a particular disease. The abnormal gene can be inherited from either parent or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from an affected parent to an offspring is 50% for each pregnancy. The risk is the same for males and females.
In some individuals, the disorder is due to a spontaneous (de novo) genetic mutation that oc-curs in the egg or sperm cell. In such situations, the disorder is not inherited from the parents.
HSAN1E affects both genders equally. Due to the complexity of disease and relatively lack of awareness of this disease, HSAN1E is often misdiagnosed or undiagnosed, making it difficult to assess its prevalence and incidence in the population.
A diagnosis of HSAN1E may be suspected based on the identification of the three main symptoms, a detailed patient history, and a family history. DNA testing for mutations in the DNMT1 gene is necessary to confirm the diagnosis of HSAN1E.
Clinical Testing and Work-up
Nerve conduction studies (NCS) are a standard test for diagnosing peripheral neuropathy. These studies are tests that measure how well individual nerves can send an electrical signal from the spinal cord to the muscles. NCS can determine nerve damage and destruction.
A complete hearing test should be done as well as testing for cognitive function which often shows up in later stage. Individuals who test positive for HSN1E should continue with regular check-ups for hearing tests and clinical testing for dementia.
Treatment
The treatment of HSAN1E is management of symptoms. Treatment may require a team of specialists including a neurologist, audiologist, and podiatrist.
Prompt recognition and treatment of wounds on affected areas (e.g. the feet) is critical. Ulcera-tion of the feet of individuals with HSAN1E is extremely similar to ulcers found on the feet of individuals with diabetic neuropathy. Therefore, treatment of foot ulcerations and infections may follow similar guidelines. Such treatment can include medical removal of diseased skin and tissue (debridement), applying medications and dressing to the wound, and keeping the wound clean and bandaged. Antibiotics may be used to treat infection.
Affected individuals should receive instruction on proper care of their feet, including avoiding risk factors for developing foot ulceration such as removing sources of pressure (e.g. shoes with pressure points). It is recommended that affected individuals receive routine foot care from a diabetic clinic or a podiatrist familiar with the treatment of diabetic foot ulcers.
Shooting pains may be treated with medications commonly used for peripheral neuropathies including amitryptiline, carbamazepine, and gabapentin.
Hearing aides are effective for the hearing loss. As the hearing loss progresses, stronger hearing aids are prescribed.
Sedatives or antipsychotic drugs are often prescribed for the symptoms that are associated with dementia (i.e., roaming behavior, extreme restlessness, delusions, and hallucinations).
As HSAN1E progresses, partners and caregivers may need help from support groups.
Genetic counseling is recommended for individuals with HSAN1 and their family members.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov.
All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
For information about clinical trials sponsored by private sources, contact: www.centerwatch.com
Some current clinical trials also are posted on the following page on the NORD website: https://rarediseases.org/living-with-a-rare-disease/find-clinical-trials/
For information about clinical trials conducted in Europe, contact:
https://www.clinicaltrialsregister.eu/
JOURNAL ARTICLES
Baets J, Duan X, Wu Y,et al. Defects of mutant DNMT1 are linked to a spectrum of neurologi-cal disorders. Brain. 2015;138(4):845-861. doi:10.1093/brain/awv010. https://www.ncbi.nlm.nih.gov/pubmed/25678562
Hurley D. Wide Variety of Neurological Disorders Linked to Mutations of Epigenetic Regula-tor. Neurology Today. 2015;15(11):1-19. doi:10.1097/01.nt.0000466928.31108.c4.
Klein CJ, Bird T, Ertekin-Taner N, et al. DNMT1 mutation hot spot causes varied phenotypes of HSAN1 with dementia and hearing loss. Neurology 2013 Feb 26;80(9):824-8. doi: 10.1212/WNL.0b013e318284076d. Epub 2013 Jan 30. https://www.ncbi.nlm.nih.gov/pubmed/23365052
INTERNET
DNMT1 gene โ Genetics Home Reference. U.S National Library of Medicine. https://ghr.nlm.nih.gov/gene/dnmt1 Published November 2012. Accessed February 2, 2017.
Klein CJ. DNMT1-Related Dementia, Deafness, and Sensory Neuropathy โ GeneReviewsยฎ โ NCBI Bookshelf. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/n/gene/dnmt1-ddsn/?report=reader Last Revision: May 17, 2012. Accessed February 2, 2017.
Online Mendelian Inheritance in Man. NEUROPATHY, HEREDITARY SENSORY. Available at: https://omim.org/entry/614116 Last Update: 10/21/2016. Accessed February 2, 2017.
NORD strives to open new assistance programs as funding allows. If we donโt have a program for you now, please continue to check back with us.
NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.
Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORDโs mission.
Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.
Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/The information provided on this page is for informational purposes only. The National Organization for Rare Disorders (NORD) does not endorse the information presented. The content has been gathered in partnership with the MONDO Disease Ontology. Please consult with a healthcare professional for medical advice and treatment.
The Genetic and Rare Diseases Information Center (GARD) has information and resources for patients, caregivers, and families that may be helpful before and after diagnosis of this condition. GARD is a program of the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
View reportOrphanet has a summary about this condition that may include information on the diagnosis, care, and treatment as well as other resources. Some of the information and resources are available in languages other than English. The summary may include medical terms, so we encourage you to share and discuss this information with your doctor. Orphanet is the French National Institute for Health and Medical Research and the Health Programme of the European Union.
View reportOnline Mendelian Inheritance In Man (OMIM) has a summary of published research about this condition and includes references from the medical literature. The summary contains medical and scientific terms, so we encourage you to share and discuss this information with your doctor. OMIM is authored and edited at the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine.
View report